Clinical peptide and protein quantification by mass spectrometry (MS)

Stefan K G Grebe, Ravinder Jit Singh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

MS quantitation of peptides/proteins has been slow to be adopted by clinical laboratories. The reasons are: (i) lesser perceived need for assay improvement of protein/peptide immunometric immuonassays (IAs) compared to competitive IAs, (ii) increased demands peptides/proteins place on mass accuracy/resolution, (iii) limitations of current instrumentation, (iv) stickiness of peptides/proteins, (v) large number of serum peptides/proteins and their broad range of concentrations.However, MS can (i) facilitate assay harmonization, (ii) identify clinically relevant protein-isoforms, (iii) solve the antibody interference and "hooking" artefacts of immunometric IAs, and (iv) facilitate biomarker verification/validation.Consequently, the last 10-15 years have seen steady growth in peptide/protein MS assay-development. Common protocols are emerging; most can be performed on triple quadrupole instruments. Affinity enrichment, with antibodies against analyte or proteotypic peptides, is commonly used. Assay performance characteristics are similar to IAs.The future will see standardization of assay validation/quality-control requirements and increasing use of multi-target assays.

Original languageEnglish (US)
JournalTrends in Analytical Chemistry
DOIs
StateAccepted/In press - 2016

Fingerprint

peptide
Mass spectrometry
mass spectrometry
Assays
Peptides
assay
protein
Proteins
antibody
Clinical laboratories
Antibodies
Biomarkers
standardization
quality control
Standardization
instrumentation
Quality control
artifact
biomarker
serum

Keywords

  • Assay-harmonization
  • Clinical
  • Fragments
  • Immunoassay limitations
  • Isoforms
  • Laboratory-testing
  • Mass spectrometry
  • Peptide
  • Protein
  • Quantitation

ASJC Scopus subject areas

  • Analytical Chemistry
  • Spectroscopy
  • Environmental Chemistry

Cite this

Clinical peptide and protein quantification by mass spectrometry (MS). / Grebe, Stefan K G; Singh, Ravinder Jit.

In: Trends in Analytical Chemistry, 2016.

Research output: Contribution to journalArticle

@article{544463dca2b2487a9bb462ba5b400177,
title = "Clinical peptide and protein quantification by mass spectrometry (MS)",
abstract = "MS quantitation of peptides/proteins has been slow to be adopted by clinical laboratories. The reasons are: (i) lesser perceived need for assay improvement of protein/peptide immunometric immuonassays (IAs) compared to competitive IAs, (ii) increased demands peptides/proteins place on mass accuracy/resolution, (iii) limitations of current instrumentation, (iv) stickiness of peptides/proteins, (v) large number of serum peptides/proteins and their broad range of concentrations.However, MS can (i) facilitate assay harmonization, (ii) identify clinically relevant protein-isoforms, (iii) solve the antibody interference and {"}hooking{"} artefacts of immunometric IAs, and (iv) facilitate biomarker verification/validation.Consequently, the last 10-15 years have seen steady growth in peptide/protein MS assay-development. Common protocols are emerging; most can be performed on triple quadrupole instruments. Affinity enrichment, with antibodies against analyte or proteotypic peptides, is commonly used. Assay performance characteristics are similar to IAs.The future will see standardization of assay validation/quality-control requirements and increasing use of multi-target assays.",
keywords = "Assay-harmonization, Clinical, Fragments, Immunoassay limitations, Isoforms, Laboratory-testing, Mass spectrometry, Peptide, Protein, Quantitation",
author = "Grebe, {Stefan K G} and Singh, {Ravinder Jit}",
year = "2016",
doi = "10.1016/j.trac.2016.01.026",
language = "English (US)",
journal = "TrAC - Trends in Analytical Chemistry",
issn = "0165-9936",
publisher = "Elsevier",

}

TY - JOUR

T1 - Clinical peptide and protein quantification by mass spectrometry (MS)

AU - Grebe, Stefan K G

AU - Singh, Ravinder Jit

PY - 2016

Y1 - 2016

N2 - MS quantitation of peptides/proteins has been slow to be adopted by clinical laboratories. The reasons are: (i) lesser perceived need for assay improvement of protein/peptide immunometric immuonassays (IAs) compared to competitive IAs, (ii) increased demands peptides/proteins place on mass accuracy/resolution, (iii) limitations of current instrumentation, (iv) stickiness of peptides/proteins, (v) large number of serum peptides/proteins and their broad range of concentrations.However, MS can (i) facilitate assay harmonization, (ii) identify clinically relevant protein-isoforms, (iii) solve the antibody interference and "hooking" artefacts of immunometric IAs, and (iv) facilitate biomarker verification/validation.Consequently, the last 10-15 years have seen steady growth in peptide/protein MS assay-development. Common protocols are emerging; most can be performed on triple quadrupole instruments. Affinity enrichment, with antibodies against analyte or proteotypic peptides, is commonly used. Assay performance characteristics are similar to IAs.The future will see standardization of assay validation/quality-control requirements and increasing use of multi-target assays.

AB - MS quantitation of peptides/proteins has been slow to be adopted by clinical laboratories. The reasons are: (i) lesser perceived need for assay improvement of protein/peptide immunometric immuonassays (IAs) compared to competitive IAs, (ii) increased demands peptides/proteins place on mass accuracy/resolution, (iii) limitations of current instrumentation, (iv) stickiness of peptides/proteins, (v) large number of serum peptides/proteins and their broad range of concentrations.However, MS can (i) facilitate assay harmonization, (ii) identify clinically relevant protein-isoforms, (iii) solve the antibody interference and "hooking" artefacts of immunometric IAs, and (iv) facilitate biomarker verification/validation.Consequently, the last 10-15 years have seen steady growth in peptide/protein MS assay-development. Common protocols are emerging; most can be performed on triple quadrupole instruments. Affinity enrichment, with antibodies against analyte or proteotypic peptides, is commonly used. Assay performance characteristics are similar to IAs.The future will see standardization of assay validation/quality-control requirements and increasing use of multi-target assays.

KW - Assay-harmonization

KW - Clinical

KW - Fragments

KW - Immunoassay limitations

KW - Isoforms

KW - Laboratory-testing

KW - Mass spectrometry

KW - Peptide

KW - Protein

KW - Quantitation

UR - http://www.scopus.com/inward/record.url?scp=84959257167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959257167&partnerID=8YFLogxK

U2 - 10.1016/j.trac.2016.01.026

DO - 10.1016/j.trac.2016.01.026

M3 - Article

AN - SCOPUS:84959257167

JO - TrAC - Trends in Analytical Chemistry

JF - TrAC - Trends in Analytical Chemistry

SN - 0165-9936

ER -